China NMPA Accepts New Indication Application for Kelun-Biotech’s SAC-TMT
China’s NMPA accepted a new indication application for Sichuan Kelun-Biotech’s sacituzumab tirumotecan (SAC-TMT).
Related stories
Xi Reaffirms Purge of 33 Senior Chinese Officials
Xi Jinping reaffirmed the purge of 33 senior officials and strengthened discipline within the Chinese Communist Party.
M impact | REGULATION | Oct 29, 2026, 01:35 PM UTC
Epigral Receives Tax Assessment Order and Demand Notice for 281.1 Million Rupees
M impact | REGULATION | Oct 29, 2026, 01:26 PM UTC
Rogers Ordered to Pay CA$15 Million in Marketing Case
Rogers Communications was ordered to pay a CA$15 million penalty in a case involving its “Infinite Wireless Plans” marketing.
M impact | REGULATION | Oct 29, 2026, 01:25 PM UTC
DOJ Announces Fraud Charges in Addiction Treatment Case
The U.S. Department of Justice announced fraud charges related to addiction treatment, according to the headline.
L impact | REGULATION | Oct 29, 2026, 01:20 PM UTC
Rogers Ordered to Pay C$15 Million Penalty Over Wireless Plan Marketing
Canada's Competition Tribunal ruled in favor of the country's antitrust regulator over Rogers' marketing of its “Infinite” unlimited-data wireless plans. The penalty is C$15 millio
M impact | REGULATION | Oct 29, 2026, 01:11 PM UTC
French Appeals Court Upholds Interim Measures Against Meta Over News Payments
A Paris appeals court upheld interim measures requiring Meta to make payments tied to news content after talks with French press organizations failed.
M impact | REGULATION | Oct 29, 2026, 01:06 PM UTC